Printer Friendly

SCICLONE PHARMACEUTICALS TO USE NEW CLINICAL DATA CONFIRMING THYMOSIN ALPHA 1'S SUPERIOR EFFECTIVENESS IN TREATING HEPATITIS B

 SCICLONE PHARMACEUTICALS TO USE NEW CLINICAL DATA CONFIRMING


THYMOSIN ALPHA 1'S SUPERIOR EFFECTIVENESS IN TREATING HEPATITIS B
 SAN MATEO, Calif., April 14 /PRNewswire/ -- SciClone Pharmaceuticals Inc. (NASDAQ/NMS: SCLN) announced today that it will utilize clinical trial data from a recently published Italian study of the use if thymosin alpha 1 to treat chronic hepatitis B in regulatory filings that it plans to make in the future in its international territories, particularly the Far East.
 Preliminary results from this new trial were presented earlier this month at the Second International Meeting on Therapies for Diseases of the Liver, and showed that thymosin alpha 1 was twice as effective as alpha interferon in successfully clearing the hepatitis B virus DNA from patients. Thymosin alpha 1 was more effective than alpha interferon, the only drug currently approved to treat hepatitis B, in all criteria examined during this trial.
 The newly published Italian trial is sponsored by Sclavo, S.p.a., an Italian pharmaceutical company that has rights to thymosin alpha 1 in Italy, Spain and Portugal. When completed later this year, the trial will have tested 70 patients, half of which will have been given thymosin alpha 1 and the balance given alpha interferon.
 The preliminary data from this trial that was presented at the Liver Meeting showed results from the first 14 patients to have completed the study. Among those 14 patients, seven received thymosin and seven received alpha interferon. Six of the seven thymosin patients showed clearance of the hepatitis B virus DNA versus only three of the seven interferon patients.
 These results, while preliminary, are consistent with previously published data about the efficacy of both thymosin alpha 1 and alpha interferon. In an earlier published Phase II study sponsored by the U.S. Food & Drug Administration, thymosin achieved positive response against chronic active hepatitis B in 75 percent of treated patients, while in a separate pivotal trial, alpha interferon achieved positive response in just 37 percent of treated patients.
 Philip Vander Werf, president of SciClone, stated that "these new Italian results are quite impressive, in that, while preliminary, they confirm thymosin alpha 1's efficacy in this very serious disease. We are aware that Sclavo already has pending a New Drug Application in Italy for use of thymosin alpha 1 in treating primary immune deficiencies as found in patients suffering from Down's Syndrome, Ataxia Telangiectasia and Mucocus Candidiasis.
 "These new clinical trial results will help support an additional indication -- treatment of chronic hepatitis B -- expected to be filed with the Italian Ministry of Health at the end of 1992 or early in 1993."
 Based on SciClone's agreements, "the company could use these data as well as the U.S. data for filing for approvals in a number of countries in its territory," Vander Werf said.
 SciClone's exclusive license rights to thymosin alpha 1 include countries where more than 90 percent of the world's individuals suffering from hepatitis B reside -- some 280 million people.
 SciClone Pharmaceuticals Inc. is primarily engaged in the acquisition, development and marketing of pharmaceuticals on a worldwide basis. The company's primary focus is on the therapeutic areas of infectious diseases (such as hepatitis B), cancers and immune system disorders. Within these areas, SciClone concentrates on indications that are chronic or life threatening and which place major cost burdens on the world's health care systems.
 -0- 4/14/92
 /CONTACT: Philip Vander Werf or Thomas E. Moore of SciClone Pharmaceuticals Inc., 415-358-3456/
 (SCLN) CO: SciClone Pharmaceuticals Inc. ST: California IN: MTC SU:


DG-MM -- SF010 -- 8336 04/14/92 13:53 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 14, 1992
Words:593
Previous Article:PARAMOUNT PICTURES PROMOTES RAE ANN DEL POZZO TO VICE PRESIDENT, FACILITIES OPERATIONS, FOR THE STUDIO GROUP
Next Article:FEDERAL SCREW WORKS REPORTS EARNINGS


Related Articles
SCHERING-PLOUGH LICENSES FROM SCICLONE POTENTIAL HEPATITIS TREATMENT IN JAPAN
SCICLONE PHARMACEUTICALS ANNOUNCES CLINICAL DEVELOPMENT/COMMERCIALIZATION AGREEMENT WITH SCHERING-PLOUGH K.K.
ALPHA 1 BIOMEDICALS ANNOUNCES MANUFACTURING AGREEMENT FOR THYMOSIN ALPHA 1
ALPHA 1 BIOMEDICALS ANNOUNCES INTERIM ARBITRATION RULING
SCICLONE RESPONDS TO ALPHA 1 PRELIMINARY TRIAL REPORT
SCICLONE PHARMACEUTICALS ANNOUNCES EXCLUSIVE LICENSING AGREEMENT FOR THYMOSIN ALPHA 1
SCICLONE PHARMACEUTICALS CLOSES LICENSING AGREEMENT FOR THYMOSIN ALPHA 1
Italian Researchers Report Statistically Significant Results in Hepatitis B Trial Using Thymosin Alpha 1
SciClone Reports Antiviral Effects of ZADAXIN(R) Thymosin Alpha 1 at International Hepatitis Conference
SciClone's ZADAXIN(R) Plus Chemotherapy Inhibits Cancerous Tumors in Mice, Study Shows.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters